Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Geron Corporation stock logo
GERN
Geron
$1.24
-3.9%
$1.43
$1.17
$4.89
$789.78M0.6411.18 million shs5.29 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.00
$6.86
$5.01
$17.81
$1.13B2.696.16 million shs2.59 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.35
-2.2%
$1.33
$1.21
$2.04
$1.07B1.343.83 million shs2.53 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$4.78
-1.6%
$4.53
$3.81
$6.37
$281.69M0.68594,967 shs295,616 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Geron Corporation stock logo
GERN
Geron
+1.57%-6.52%-11.03%+1.57%-72.90%
Novavax, Inc. stock logo
NVAX
Novavax
+0.57%-1.41%+7.86%+16.67%-55.84%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+1.47%+1.47%+6.98%-2.82%-2.82%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
+1.04%-2.61%+8.24%+12.24%-21.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Geron Corporation stock logo
GERN
Geron
3.4585 of 5 stars
3.32.00.01.32.71.70.6
Novavax, Inc. stock logo
NVAX
Novavax
4.3399 of 5 stars
3.11.00.04.71.60.83.1
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.0157 of 5 stars
3.50.00.04.42.33.30.6
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.7234 of 5 stars
3.84.00.04.21.63.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Geron Corporation stock logo
GERN
Geron
2.60
Moderate Buy$4.61271.86% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$17.00142.86% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
3.00
Buy$2.75103.70% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50245.19% Upside

Current Analyst Ratings Breakdown

Latest VNDA, NVAX, OPK, and GERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Geron Corporation stock logo
GERN
Geron
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$1.00
7/8/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
5/13/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
5/8/2025
Geron Corporation stock logo
GERN
Geron
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.50
5/7/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Geron Corporation stock logo
GERN
Geron
$76.99M10.26N/AN/A$0.46 per share2.70
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.66N/AN/A($3.89) per share-1.80
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.50$0.07 per share19.77$2.00 per share0.68
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$198.77M1.42N/AN/A$9.24 per share0.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Geron Corporation stock logo
GERN
Geron
-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.6487.500.0638.14%-115.51%29.99%8/14/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)

Latest VNDA, NVAX, OPK, and GERN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Geron Corporation stock logo
GERN
Geron
-$0.03N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.12N/AN/AN/AN/AN/A
8/6/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.11N/AN/AN/A$165.74 millionN/A
7/30/2025Q2 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.34N/AN/AN/A$54.77 millionN/A
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/7/2025Q1 2025
Geron Corporation stock logo
GERN
Geron
-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Geron Corporation stock logo
GERN
Geron
0.44
7.87
6.97
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
3.93
3.91

Institutional Ownership

CompanyInstitutional Ownership
Geron Corporation stock logo
GERN
Geron
73.71%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%

Insider Ownership

CompanyInsider Ownership
Geron Corporation stock logo
GERN
Geron
7.42%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Geron Corporation stock logo
GERN
Geron
70636.92 million589.66 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.04 millionOptionable

Recent News About These Companies

VNDA - Vanda Pharmaceuticals Inc Chart - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Geron stock logo

Geron NASDAQ:GERN

$1.24 -0.05 (-3.88%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 +0.01 (+1.21%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$7.00 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$7.00 0.00 (-0.07%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.35 -0.03 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 +0.01 (+0.74%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$4.78 -0.08 (-1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$4.78 0.00 (-0.10%)
As of 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.